We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genetix Grp | LSE:GTX | London | Ordinary Share | GB0001276863 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 84.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
18/11/2005 23:56 | i'm back in after a long time out of these! Anyone else around? | jpuff | |
23/3/2005 11:50 | dont wast your money | dpd | |
03/3/2005 13:23 | Just had a few days away, and its nice to come back to a little positive direction. I missed the results the other day Which after a quick glance look very reasonable, and wish them the best in gaining a decent slice of.... 'Our key priority in 2005 is to concentrate activity on the potentially significant markets within cell biology and penetrate these as quickly as possible' Also still a quite board, with a price that looks far from overstretched. | games | |
03/3/2005 10:36 | bought a few today.Volumes look encouraging | kennerland | |
03/3/2005 08:53 | like it even more - up 7% today | 25october1969 | |
02/3/2005 16:32 | And at 4.25-4.30 it suddenly shoots up 1.5 and on line can sell 50,000 and only buy 2500..............I have no idea what it is but I like it | 25october1969 | |
02/3/2005 15:56 | ANyone any idea what is happening with the volume today, almost 3 million so far today and no price movement. One definate X of 500,000 but at least 1.5m buys | 25october1969 | |
15/2/2005 10:21 | Hi Roy, Ref earlier post: Its the Genetix AliQuot product, and BMS (Bristol-Myers Squibb) who were contemplating using the product. (arond mid Jan) As for the cash balance, sure its nice to have a pile, but imo its too high a percentage of the mkt-cap at the moment, and will more than likely act as a dampner till profits/eps are somewhat higher. | games | |
15/2/2005 10:01 | HI games Looks an interesting share and I see the cash balance very much as a positive. The next set of results are obviously important as much for the outlook as for the figures have bought in over the last few days - before todays price rise I am pleased to say cheers Roy | 25october1969 | |
14/2/2005 21:57 | Bit of a sleepy thread this one, is anyone lurking out there with an opinion on these. £34m mkt cap £21.7m cash, approx £25m nav (without the intangibles) H1 sales (June04) of £6.7m (+38%) Adjusted EPS (excluding goodwill) up 51%; basic EPS up 100% downside: pre-tax profit of £0.4 million up 78%, which would be fine with a mkt cap around £12m especially if the finals on March 1st come in good, but the large amount of cash will be a dampner. New product (clonepix. FL) announced very recently, which has gained some interest from the majors, and i did come across a snip where a large company had the product short-listed, that has yet has not being mentioned by the company. veiws anyone? | games | |
21/11/2003 11:35 | Ultrasis (ULT) a potential 10 to 20 bagger short-term imo. | qazwsx123 | |
05/11/2003 13:45 | pfb5 I seek not attention, I seek investors! Good to have some company. p.s. I don't understand my last two posts either! ;) | mad4it | |
05/11/2003 13:36 | mad41T: I don't understand your last two posts, but if you're seeking attention, you're not the only one who's watching - I own some of these too! | pfb5 | |
03/11/2003 16:43 | " I wandered lonely as a cloud. " | mad4it | |
29/10/2003 15:21 | lovecustard - 14 May'03 - 08:36 - 5 of 6 last mm on offer .................... He's right you know! lol! | mad4it | |
29/10/2003 13:30 | Anyone watching these ? I bought a few at 48p and 60p. This looks like a good potential recovery story to me. A profitable company, with Approx 29p in cash, supplying state of the art equipment to the biotech industry. Recent director purchase of 50k at 55p and it's good to see the options issued to the new COO at 51.5p are performance related. I remember when GTX floated, their products were considered second to none. We are seeing a lot of growth in the biotech areas where they are supplying products and their products are still seen as a must have by the big Pharma companies (see below). Worth a punt I reckon. Here's the most recent, relevant info: 29/07/03: LONDON (AFX) - Genetix Group PLC said sales fell to 4.9 mln stg from 6.3 mln stg in a continuing difficult trading environment. For the six months to June 30, pre-tax profit fell to 0.2 million from 1 mln stg in 2002. It said conditions were challenging throughout the first six months of 2003. Difficulties for the biotechnology sector in raising funds, cutbacks and delays in academic grants, and pressure on pharmaceutical companies to orientate their R&D towards late-stage products have put pressure on supplier companies such as Genetix, it said. But despite these "tough conditions", Genetix remains profitable overall and financially strong with 21.4 mln stg of cash in the bank and an innovative pipeline of new products to generate future revenue, it said. Looking ahead, it said it remains confident in the company's ability to increase its market share as well as the opportunities to enter new markets. But in view of the continuing uncertain trading environment, the company remain cautious about prospects for 2003, although it anticipates maintaining a strong cash position of over 20 mln stg throughout the year. "We are encouraged by recent signs of a return of investor confidence in the biotech sector on the back of promising clinical data and product approvals, which underline the long-term promise of the industry," it said. .................... RNS Number:5130O Genetix Group PLC 11 August 2003 Genetix launches the aliQuot liquid handler Pre-launch orders placed by two of the top three major pharmaceutical companies Boston, USA, 11 August 2003 - Genetix Group plc (LSE: GTX), the genomics and proteomics technology group, today announces the launch of the aliQuot, an automated solution for the low volume dispensing of reagents, chemicals, cells, beads, reaction mixes and other media, at the Drug Discovery Technology conference in Boston, USA. The aliQuot, a desktop machine, uses a proprietary fast pressure-timing dispense mechanism to fill a 1536-well plate with one microlitre in under 30 seconds. The level of accuracy (well-to-well CV of approximately 5%) is unsurpassed by any other instrument in its price bracket. The major markets for this product will be drug discovery, forensics, genetic screening, genomics research and high throughput screening. Low volume dispensing is economically beneficial to pharmaceutical companies when testing compounds with reagents which can cost thousands of dollars per millilitre. Using smaller volumes in these assays enables a greater number of tests to be carried out, or the same number of tests at less cost. Another feature of the aliQuot which reduces the cost of assays is a backfilling function which allows unused compound or reagent remaining in the dispensing pipes to be flushed back into the reservoir bottle for future use. Future developments are likely to include the simultaneous dispensing of up to eight reagents. Julian Burke PhD, Chief Scientific Officer of Genetix, commented: "The aliQuot makes small volume dispensing accessible to laboratories previously unable to conduct assays on this scale because of budget or space constraints, it also offers a more economical solution to those larger companies already conducting tests on this level. Building on skills acquired during the development of the Qfill2 liquid handler, Genetix is able to offer this small volume capability at excellent speed and accuracy to it customers. Multiple pre-launch orders have already been received by two of the three leading pharmaceutical companies." | mad4it | |
12/8/2003 09:48 | It's on it's way back down again now, think I have missed the boat to day trade this one. | speny | |
12/8/2003 08:53 | This share will close at 90p today | tcpipman | |
12/8/2003 08:33 | Yes me, bought pre-market yesterday.Last line in statement was most important:-"Multiple pre-launch orders have already been received by two of the leading pharmaceutical companies" | steadyeddy | |
12/8/2003 08:30 | in at 43p mate! | tonyleongson | |
12/8/2003 07:41 | Up 19% today - days biggest gainer. Is anyone watching? | ok,yah | |
11/8/2003 13:43 | Yep, cash rich company that is profit making. Twenty one million quid in the bank without cash burn. Looks like a fairly low risk entry into a rapidly growing area - Gene Research. Todays announcement - two products launched with orders already in the bag:- Genetix Group PLC, which makes equipment for research into human and plant genomics, said it has launched ClonePix, a new instrument for mammalian cell colony picking, which the company says is the first step in the production and selection of monoclonal antibodies. "Monoclonal antibody production is an increasingly important area of focus for biotechnology companies," Genetix said. "Around 25 pct of biopharmaceutical drugs currently in Phase II trials are based on monoclonal antibodies." Genetix launched the product at the Drug Discovery Technology conference in Boston in the US. Genetix also said it launched aliQuot, an automated solution for the low volume dispensing of reagents, chemicals, cells, beads, reaction mixes and other media. The major markets for this product will be drug discovery, forensics, genetic screening, genomics research and high throughput screening, it said. bam | ok,yah | |
08/8/2003 08:42 | 8 August 2003, Alizyme (AZM): Superb announcement from Alizyme today regarding out-licensing deal with Takeda, the largest pharmaceutical company in Japan, for Japanese rights to ATL-962 for the treatment of obesity and all related diseases. * Exclusive rights for Japan. * Total agreement worth up to US$42 million: ..........US$2 million payable immediately ..........US$40 million payable on future milestones/events ..........US $42 total (i.e. between now and ATL-962 reaching the market) * Double digit royalties on future sales by Takeda in Japan. * All development costs in Japan paid by Takeda. | qazwsx123 | |
23/5/2003 07:48 | westex Click on 'Fundamentals' and it looks to me like there's 72.7m shares in issue and £20.87m in the bank as at 31/12/02, so isn't that 28.7p per share? CEO, Chairman, Directors & cronies, employees, already hold more than two-thirds of the shares in issue. MBO unlikely, basically they already control it? | pfb5 |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions